Healthcare provider profile · identity verified

Bruno J. Lewin, MD

Family Practice · LOS ANGELES, CA · NPI 1003983990

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Azithromycin	Azithromycin	534	491
Atorvastatin Calcium	Atorvastatin Calcium	395	143
Typhim Vi	Typhoid Vi Polysacch Vaccine	230	230
Lisinopril	Lisinopril	182	61
Losartan Potassium	Losartan Potassium	175	56
Atovaquone-Proguanil Hcl	Atovaquone/Proguanil Hcl	168	161
Amlodipine Besylate	Amlodipine Besylate	150	52
Metformin Hcl	Metformin Hcl	120	40
Hydrochlorothiazide	Hydrochlorothiazide	107	40
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	107	40
Omeprazole	Omeprazole	106	41
Levothyroxine Sodium	Levothyroxine Sodium	105	37
Simvastatin	Simvastatin	103	35
Metformin Hcl Er	Metformin Hcl	98	42
Rosuvastatin Calcium	Rosuvastatin Calcium	83	34
Finasteride	Finasteride	74	19
Alendronate Sodium	Alendronate Sodium	71	27
Glipizide	Glipizide	66	23
Havrix	Hepatitis A Virus Vaccine/Pf	66	66
Jardiance	Empagliflozin	64	21
Gabapentin	Gabapentin	56	25
Acetazolamide	Acetazolamide	53	47
Tamsulosin Hcl	Tamsulosin Hcl	53	17
Atenolol	Atenolol	49	15
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	48	14
Bisoprolol Fumarate	Bisoprolol Fumarate	46	13
Scopolamine	Scopolamine	44	42
Doxycycline Monohydrate	Doxycycline Monohydrate	41	34
Pradaxa	Dabigatran Etexilate Mesylate	40	12
Ipol	Poliomyelitis Vaccine, Killed	36	36
Allopurinol	Allopurinol	34	14
Twinrix	Hepatitis A And B Vaccine/Pf	34	26
Triamcinolone Acetonide	Triamcinolone Acetonide	33	21
Clopidogrel	Clopidogrel Bisulfate	32	12
Terazosin Hcl	Terazosin Hcl	31	14
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	30	30
Glipizide-Metformin	Glipizide/Metformin Hcl	29	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	28	27
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	27	14
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	27	suppressed
Glipizide Er	Glipizide	26	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	26	suppressed
Famotidine	Famotidine	25	13
Fluticasone Propionate	Fluticasone Propionate	24	11
Potassium Chloride	Potassium Chloride	24	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	23	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	23	suppressed
Xarelto	Rivaroxaban	21	suppressed
Meloxicam	Meloxicam	20	suppressed
Carvedilol	Carvedilol	19	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	19	suppressed
Furosemide	Furosemide	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	17	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	16	16
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	16	16
Humulin N	Insulin Nph Human Isophane	16	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	16	suppressed
Ibandronate Sodium	Ibandronate Sodium	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	16	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	16	suppressed
Yf-Vax	Yellow Fever Vaccine Live/Pf	16	16
Alvesco	Ciclesonide	15	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Montelukast Sodium	Montelukast Sodium	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Trazodone Hcl	Trazodone Hcl	15	suppressed
Ciclopirox	Ciclopirox	14	suppressed
Duloxetine Hcl	Duloxetine Hcl	14	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Naproxen	Naproxen	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error